Johnson & Johnson Innovation JLABS @ TMC, Houston.
With a lead investment from the UK-based Wellcome Trust, a premier international medical foundation, CorInnova is developing a non-blood contacting cardiac assist device. CorInnova's device is a transformative biventricular device to treat acute heart failure. The technology will create a new paradigm for treatment. The device is designed to eliminate 40% of the adverse events associated with existing cardiac assist technologies, and may expand eligible patients by 3 to 4 times. The device may reverse the progression of HF, a blockbuster application. The device deploys minimally invasively into the pericardial sac in under 30 seconds, and has shown the ability to increase cardiac output by up to 50%. Addressable markets are up to $8 billion.
Location: United States, Texas, Houston
Employees: 11-50
Total raised: $6.1M
Investors 5
| Date | Name | Website |
| - | SWPDC | swpdc.org/ |
| - | TMC Ventur... | tmcventure... |
| - | Cowtown An... | cowtownang... |
| - | Frontera T... | fronterate... |
| 13.04.2023 | Keiretsu F... | keiretsufo... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 30.10.2017 | - | $6.1M | - | - |
Mentions in press and media 3
| Date | Title | Description | Source |
| 29.04.2019 | Pitch Perfect Winner Spotlight: CorInnova wants to change th... | Additionally, the high eligibility requirements for the procedure used to implant these pumps mean t... | medcitynew... |
| 30.10.2017 | Corinnova Nets $6.1M from Wellcome for Heart Failure Medical... | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Houston—More than 12 million peopl... | xconomy.co... |
| - | Pitch Perfect Winner Spotlight: CorInnova wants to change th... | From left: MedCity News Editor in Chief Arundhati Parmar, CorInnova CEO William Altman, and MHIN Pre... | medcitynew... |